TV News LIES

Tuesday, Mar 19th

Last update06:28:22 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Nearly 130,000 children exposed to lead-tainted drinking water in Chicago

Chicago childen eexpoed to lead in tap water About 129,000 Chicago children under the age of six are exposed to poisonous lead in their...

A simple blood test can detect colorectal cancer early, study finds

Blood test can detect colon cancer At a time when colorectal cancer is on the rise, a new study finds the disease...

‘Alarming’ rise in Americans with long Covid symptoms

Long COVID in US Some 6.8% of American adults are currently experiencing long Covid symptoms, according to a new survey...

Kamala Harris declares 'health crisis' in historic visit to abortion clinic in Minnesota

VP HarrisVice President Kamala Harris made a historic visit to an abortion clinic in the Twin Cities...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!